$79.75
+1.64 (+2.10%)
At Close: Jul 13, 2026
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
10:51am, Wednesday, 01'st Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED vs. MDT: Which Medical Stock Has More Upside Potential?
02:41pm, Monday, 29'th Jun 2026
Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
10:41am, Friday, 26'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 22'nd Jun 2026
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
11:31am, Monday, 22'nd Jun 2026
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
07:40am, Monday, 22'nd Jun 2026
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas
Here's How Innovation Fuels Globus Medical's Growth Momentum
11:36am, Monday, 15'th Jun 2026
GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
08:00am, Friday, 12'th Jun 2026
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its res
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
11:06am, Tuesday, 09'th Jun 2026
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?
10:56am, Monday, 08'th Jun 2026
The consensus price target hints at a 38.9% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
GMED or PEN: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 05'th Jun 2026
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for th
Here's Why Globus Medical (GMED) is a Strong Value Stock
10:40am, Friday, 05'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Financial Strength Remains a Key Advantage for GMED
12:55pm, Thursday, 04'th Jun 2026
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
11:30am, Tuesday, 02'nd Jun 2026
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Globus Medical, Inc. (NYSE: GMED)
09:05am, Monday, 01'st Jun 2026
NEW YORK, June 1, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders. The investigation seeks t
Sign In
Buy GMED